概括
新的帕金森病 (PD) 治疗方法,包括新药和药物配方,为运动波动和OFF发作提供了更好的管理. 这些进展旨在提高需要Levodopa治疗的PD患者的生活质量.
科学领域:
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
背景情况:
- 帕金森病 (PD) 影响了近100万美国人,大多数患者需要接受利沃多巴治疗.
- 晚期PD阶段通常涉及运动波动,需要调整药物以控制症状.
研究的目的:
- 审查帕金森病运动波动的近期治疗进展.
- 提供基于证据的建议,以新疗法来管理OFF发作.
主要方法:
- 通过患者病例研究探索新的治疗选择.
- 专注于像阿皮卡,萨菲纳米德和伊斯特拉德菲林这样的药物.
- 考虑新的药物配方和作用机制.
主要成果:
- 在过去的十年中,出现了几种新的药物和剂型.
- 这些药物包括甲基转移酶抑制剂 (例如,opicapone) 和单胺氧化酶B抑制剂 (例如,safinamide).
- 伊斯特拉德菲林代表了帕金森病治疗的新机制.
结论:
- 新的治疗方案提供了管理帕金森病运动波动的额外策略.
- 这些进展旨在通过解决OFF发作来改善患者的生活质量.
- 基于证据的建议指导在临床实践中使用这些新型治疗方法.
相关概念视频
01:24Parkinson's Disease: Treatment
276
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
276
01:15Parkinson's Disease: Overview
557
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
557
01:37Neural Regulation
39.5K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.5K
01:28Drug Therapy
45
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
45
01:22Alzheimer's Disease: Treatment
195
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
195
01:26Psychosis: Goals of Pharmacotherapy
142
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
142